Reversible congenital hypogonadotropic hypogonadism in patients with CHD7, FGFR1 or GNRHR mutations

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Laitinen, Eeva Maria ^b   Tommiska, Johanna ^a,b   Sane, Timo ^c   Vaaralahti, Kirsi ^a,b   Toppari, Jorma ^d   Raivio, Taneli ^a,b  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; ADULTHOOD; ANAMNESIS; ANDROGEN THERAPY; ARTICLE; CHD7 GENE; CLINICAL ARTICLE; CLINICAL EXAMINATION; DISEASE COURSE; ETHNIC GROUP; FGF8 GENE; FGFR1 GENE; FINNISH; GENE; GENE MUTATION; GENETIC SCREENING; GENOTYPE; GNRH1 GENE; GNRHR GENE; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; KAL1 GENE; KALLMANN SYNDROME; KISS1 GENE; KISS1R GENE; LHBETA GENE; MALE; ORGAN GROWTH; PHENOTYPE; PROK2 GENE; PROKR2 GENE; REVERSIBLE CONGENITAL HYPOGONADOTROPIC HYPOGONADISM; TAC3 GENE; TACR3 GENE; TESTIS; WDR11 GENE;

ADOLESCENT; ADULT; DNA HELICASES; DNA-BINDING PROTEINS; GENOTYPE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; KALLMANN SYNDROME; MALE; MUTATION; PHENOTYPE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, LHRH; YOUNG ADULT;

EID: 84862549630     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039450     Document Type: Article

References (40)

1. Schwanzel-Fukuda M, Bick D, Pfaff DW, (1989) Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Brain Res Mol Brain Res 6: 311-326.
2. Seminara SB, Hayes FJ, Crowley WF Jr, (1998) Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Endocr Rev 19: 521-539.
3. Cariboni A, Maggi R, (2006) Kallmann's syndrome, a neuronal migration defect. Cell Mol Life Sci 63: 2512-2526.
4. Teixeira L, Guimiot F, Dode C, Fallet-Bianco C, Millar RP, et al. (2010) Defective migration of neuroendocrine GnRH cells in human arrhinencephalic conditions. J Clin Invest 120: 3668-3672.
5. Han TS, Bouloux PM, (2010) What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol (Oxf) 72: 731-737.
6. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, et al. (2007) Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 357: 863-873.
7. Rezvani I, DiGeorge A, Rutano J, Snyder P, (1975) Delayed puberty and anosmia; coincidence or Kallmann variant? Pediatr Res 9: 224.
8. Rogol AD, Mittal KK, White BJ, McGinniss MH, Lieblich JM, et al. (1980) HLA-compatible paternity in two "fertile eunuchs" with congenital hypogonadotropic hypogonadism and anosmia (the Kallmann syndrome). J Clin Endocrinol Metab 51: 275-279.
9. Rowe RC, Schroeder ML, Faiman C, (1983) Testosterone-induced fertility in a patient with previously untreated s syndrome. Fertil Steril 40: 400-401.
10. Bauman A, (1986) Markedly delayed puberty or Kallmann's syndrome variant. J Androl 7: 224-227.
11. Kadva A, Di WL, Djahanbakhch O, Monson J, Silman R, (1996) Evidence for the Bauman variant in Kallmann's syndrome. Clin Endocrinol (Oxf) 44: 103-110.
12. Wortsman J, Hughes LF, (1996) Case report: olfactory function in a fertile eunuch with Kallmann syndrome. Am J Med Sci 311: 135-138.
13. Quinton R, Cheow HK, Tymms DJ, Bouloux PM, Wu FC, et al. (1999) Kallmann's syndrome: is it always for life? Clin Endocrinol (Oxf) 50: 481-485.
14. Bagatell CJ, Paulsen CA, Bremner WJ, (1994) Preservation of fertility despite subnormal gonadotropin and testosterone levels after cessation of pulsatile gonadotropin-releasing hormone therapy in a man with Kallmann's syndrome. Fertil Steril 61: 392-394.
15. Pitteloud N, Boepple PA, DeCruz S, Valkenburgh SB, Crowley WF Jr, et al. (2001) The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. J Clin Endocrinol Metab 86: 2470-2475.
16. Pitteloud N, Acierno JS Jr, Meysing AU, Dwyer AA, Hayes FJ, et al. (2005) Reversible kallmann syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the fibroblast growth factor receptor 1 gene. J Clin Endocrinol Metab 90: 1317-1322.
17. Lin L, Conway GS, Hill NR, Dattani MT, Hindmarsh PC, et al. (2006) A homozygous R262Q mutation in the gonadotropin-releasing hormone receptor presenting as constitutional delay of growth and puberty with subsequent borderline oligospermia. J Clin Endocrinol Metab 91: 5117-5121.
18. Ribeiro RS, Vieira TC, Abucham J, (2007) Reversible Kallmann syndrome: report of the first case with a KAL1 mutation and literature review. Eur J Endocrinol 156: 285-290.
19. Sinisi AA, Asci R, Bellastella G, Maione L, Esposito D, et al. (2008) Homozygous mutation in the prokineticin-receptor2 gene (Val274Asp) presenting as reversible Kallmann syndrome and persistent oligozoospermia: case report. Hum Reprod 23: 2380-2384.
20. Raivio T, Sidis Y, Plummer L, Chen H, Ma J, et al. (2009) Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 94: 4380-4390.
21. Gianetti E, Tusset C, Noel SD, Au MG, Dwyer AA, et al. (2010) TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab 95: 2857-2867.
22. Morelli A, Fibbi B, Marini M, Silvestrini E, De Vita G, et al. (2009) Dihydrotestosterone and leptin regulate gonadotropin-releasing hormone (GnRH) expression and secretion in human GnRH-secreting neuroblasts. J Sex Med 6: 397-407.
23. Zenaty D, Bretones P, Lambe C, Guemas I, David M, et al. (2006) Paediatric phenotype of Kallmann syndrome due to mutations of fibroblast growth factor receptor 1 (FGFR1). Mol Cell Endocrinol 254-255: 78-83.
24. Laitinen EM, Vaaralahti K, Tommiska J, Eklund E, Tervaniemi M, et al. (2011) Incidence, Phenotypic Features and Molecular Genetics of Kallmann Syndrome in Finland. Orphanet J Rare Dis 6: 41.
25. Koenigkam-Santos M, Santos AC, Versiani BR, Diniz PR, Junior JE, et al. (2011) Quantitative Magnetic Resonance Imaging Evaluation of the Olfactory System in Kallmann Syndrome: Correlation with a Clinical Smell Test. Neuroendocrinology 94: 209-217.
26. Achard C, Courtillot C, Lahuna O, Meduri G, Soufir JC, et al. (2009) Normal spermatogenesis in a man with mutant luteinizing hormone. N Engl J Med 361: 1856-1863.
27. Vaaralahti K, Wehkalampi K, Tommiska J, Laitinen EM, Dunkel L, et al. (2011) The role of gene defects underlying isolated hypogonadotropic hypogonadism in patients with constitutional delay of growth and puberty. Fertil Steril 95: 2756-2758.
28. Matsumoto AM, (1990) Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab 70: 282-287.
29. Dewailly D, Boucher A, Decanter C, Lagarde JP, Counis R, et al. (2002) Spontaneous pregnancy in a patient who was homozygous for the Q106R mutation in the gonadotropin-releasing hormone receptor gene. Fertil Steril 77: 1288-1291.
30. de Roux N, Young J, Misrahi M, Genet R, Chanson P, et al. (1997) A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 337: 1597-1602.
31. Blake KD, Prasad C, (2006) CHARGE syndrome. Orphanet J Rare Dis 1: 34.
32. Kim HG, Kurth I, Lan F, Meliciani I, Wenzel W, et al. (2008) Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 83: 511-519.
33. Jongmans MC, van Ravenswaaij-Arts CM, Pitteloud N, Ogata T, Sato N, et al. (2009) CHD7 mutations in patients initially diagnosed with Kallmann syndrome-the clinical overlap with CHARGE syndrome. Clin Genet 75: 65-71.
34. Dauber A, Hirschhorn JN, Picker J, Maher TA, Milunsky A, (2010) Delayed puberty due to a novel mutation in CHD7 causing CHARGE syndrome. Pediatrics 126: e1594-1598.
35. Pinto G, Abadie V, Mesnage R, Blustajn J, Cabrol S, et al. (2005) CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development. J Clin Endocrinol Metab 90: 5621-5626.
36. Bergman JE, Bocca G, Hoefsloot LH, Meiners LC, van Ravenswaaij-Arts CM, (2011) Anosmia predicts hypogonadotropic hypogonadism in CHARGE syndrome. J Pediatr 158: 474-479.
37. Feret H, McDonald-McGinn DM, Santani A, Zackai EH, (2010) Expanding the Phenotypic Overlap Between CHARGE and Kallmann Syndromes due to CHD7 Mutations. (Abstract #1671) Presented at the 60th Annual Meeting of The American Society of Human Genetics, November 3, Washington, DC.
38. Bajpai R, Chen DA, Rada-Iglesias A, Zhang J, Xiong Y, et al. (2010) CHD7 cooperates with PBAF to control multipotent neural crest formation. Nature 463: 958-962.
39. Forni PE, Taylor-Burds C, Melvin VS, Williams T, Wray S, (2011) Neural crest and ectodermal cells intermix in the nasal placode to give rise to GnRH-1 neurons, sensory neurons, and olfactory ensheathing cells. J Neurosci 31: 6915-6927.
40. Layman WS, Hurd EA, Martin DM, (2011) Reproductive dysfunction and decreased GnRH neurogenesis in a mouse model of CHARGE syndrome. Hum Mol Genet 20: 3138-3150.